NJC
Paper
90 : 10 isomeric ratio of 2c to 3c. 1H NMR (500 MHz, CDCl3) (500 MHz, CDCl3) d 7.38–7.31* (m, 2H), 7.18* (s, 1H), 7.17–7.12
d 7.33* (q, J = 8.6 Hz, 4H), 7.24 (d, J = 4.2 Hz, 2H), 7.18* (s, 1H), (m, 2H), 7.03* (t, J = 8.6 Hz, 2H), 6.94 (t, J = 8.6 Hz, 2H), 5.82
7.10 (d, J = 7.9 Hz, 2H), 5.79 (s, 1H), 5.49 (s, 1H), 3.42 (s, 2H), (s, 1H), 5.53 (s, 1H), 3.44 (s, 2H), 1.97* (s, 3H), 1.31* (s, 12H), 1.20
1.98* (s, 3H), 1.30* (s, 9H), 1.29* (s, 12H), 1.27 (s, 9H), 1.19 (s, 12H). 13C NMR (126 MHz, CDCl3) d 161.5 (d, J = 243.0 Hz),
(s, 12H). 13C NMR (101 MHz, CDCl3) d 150.2*, 148.6, 142.4*, 141.3, 136.5 (d, J = 3.0 Hz), 131.2* (d, J = 8.1 Hz), 130.6 (d, J =
137.7, 129.8, 129.4*, 128.9, 125.1, 83.6, 40.9, 34.7*, 34.5, 31.6, 7.7 Hz), 130.0, 114.9 (d, J = 20.9 Hz), 100.2*, 83.7, 40.8, 25.0*,
31.4*, 25.0*, 24.8, 16.2*. 11B NMR (128 MHz, CDCl3) d 30.07. 24.8, 15.9*. 11B NMR (128 MHz, CDCl3) d 29.98. EI-MS: [M]+.
EI-MS: [M]+. Calcd for C19H29BO2 300.23, observed 300.3.
Calcd for C15H20BFO2 262.15, observed 262.3.
2-(3-(4-Chlorophenyl)prop-1-en-2-yl)-4,4,5,5-tetramethyl-1,3,2-
2-(3-(4-Methoxyphenyl)prop-1-en-2-yl)-4,4,5,5-tetramethyl-1,3,2-
dioxaborolane (2d) and (Z)-2-(1-(4-chlorophenyl)prop-1-en-2-yl)- dioxaborolane (2i) and (Z)-2-(1-(4-methoxyphenyl)prop-1-en-2-yl)-
4,4,5,5-tetramethyl-1,3,2-dioxaborolane (3d). Synthesized by general 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (3i). Synthesized by general
procedure 4, isolated as yellow oil, 87% yield, 90 : 10 isomeric ratio procedure, isolated as an off yellow oil, 46% yield, 67 : 33 isomeric
1
2d to 3d. H NMR (500 MHz, CDCl3) d 7.31* (s, 4H), 7.22 (d, J = ratio 2i to 3i. 1H NMR (400 MHz, CDCl3) d 7.43–7.32* (m, 2H), 7.18*
8.1 Hz, 2H), 7.17* (s, 1H), 7.12 (d, J = 8.1 Hz, 2H), 5.83 (s, 1H), (d, J = 1.8 Hz, 1H), 7.14–7.05 (m, 2H), 6.92–6.85* (m, 2H), 6.85–6.77
5.53 (s, 1H), 3.43 (s, 2H), 1.96* (s, 3H), 1.31 (s, 12H), 1.21 (s, 12H). (m, 2H), 5.81 (dt, J = 3.3, 1.2 Hz, 1H), 5.51 (dt, J = 3.4, 1.6 Hz, 1H),
13C NMR (126 MHz, CDCl3) d 141.1*, 139.4, 131.6, 130.8*, 3.82* (s, 3H), 3.78 (s, 3H), 3.42 (d, J = 1.4 Hz, 2H), 2.00* (d, J =
130.6, 130.3, 128.4*, 128.3, 83.7, 41.00, 25.0*, 24.9, 16.0*. 11B NMR 1.7 Hz, 3H), 1.31* (s, 12H), 1.21 (s, 12H). 13C NMR (101 MHz,
(128 MHz, CDCl3) d 29.92. EI-MS: [M]+. Calcd for C15H20BClO2 CDCl3) d 158.8*, 157.9, 142.1*, 132. 9, 131.1*, 130.9, 130.2*, 129.6,
278.12, observed 278.1.
113.7, 113.6*, 83.6, 83.5*, 55.4, 55.4*, 40.6, 25.0*, 24.8, 16.1*.
2-(3-(3-Chlorophenyl)prop-1-en-2-yl)-4,4,5,5-tetramethyl-1,3,2- 11B NMR (128 MHz, CDCl3) d 30.21. EI-MS: [M]+. Calcd for
dioxaborolane (2e) and (Z)-2-(1-(4-chlorophenyl)prop-1-en-2-yl)- C16H23BO3 274.17, observed 274.3.
4,4,5,5-tetramethyl-1,3,2-dioxaborolane (3e). Synthesized by general
2-(3-(4-(Benzyloxy)phenyl)prop-1-en-2-yl)-4,4,5,5-tetramethyl-
procedure, isolated as yellow oil, 62% yield, 89 : 11 isomeric ratio 2e 1,3,2-dioxaborolane (2j) and (Z)-2-(1-(3-(benzyloxy)phenyl)prop-
to 3e. 1H NMR (500 MHz, CDCl3) d 7.16–6.96 (m, 4H), 5.77 (d, J = 1-en-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (3j). Synthe-
2.3 Hz, 1H), 5.48 (s, 1H), 3.36 (s, 2H), 1.92–1.86* (m, 3H), 1.23* sized by general procedure, isolated as white solid, 37%,
(s, 12H), 1.13 (s, 12H). 13C NMR (126 MHz, CDCl3) d 143.0, 140.9*, 66 : 34 isomeric ratio 2j to 3j. 1H NMR (500 MHz, CDCl3)
133.9, 130.5, 129.4, 129.4, 127.6*, 127.4, 127.2*, 126.0, 83.7, 41.4, d 7.48–7.30 (m, 5H from 2j and 7H from 3j), 7.20* (s, 1H),
25.0*, 24.8, 16.0*. EI-MS: [M]+. Calcd for C15H20BClO2 278.12, 7.12 (d, J = 7.8 Hz, 2H), 6.97* (d, J = 8.1 Hz, 0H), 6.90 (d, J =
observed 278.1.
7.8 Hz, 2H), 5.82 (s, 1H), 5.53 (s, 1H), 5.08* (s, 2H), 5.05* (s, 2H),
2-(3-(2-Chlorophenyl)prop-1-en-2-yl)-4,4,5,5-tetramethyl-1,3,2- 3.44 (s, 2H), 2.02* (s, 3H), 1.32* (s, 12H), 1.22 (s, 12H). 13C NMR
dioxaborolane (2f) and (Z)-2-(1-(2-Chlorophenyl)prop-1-en-2-yl)- (126 MHz, CDCl3) d 158.0*, 157.1, 142.0*, 137.4, 137.1*, 133.2,
4,4,5,5-tetramethyl-1,3,2-dioxaborolane (3f). Synthesized by gen- 131.1*, 131.1*, 130.2, 129.6, 128.7*, 128.7, 128.1*, 128.0, 127.7*,
eral procedure, isolated as yellow oil, 87% yield, 90 : 10 isomeric 127.6, 114.7, 114.5*, 83.6, 83.6*, 70.2, 70.1*, 40.7, 25.0*, 24.8,
1
ratio 2f to 3f. H NMR (500 MHz, CDCl3) d 7.44–7.12 (m, 4H), 16.1*. 11B NMR (128 MHz, CDCl3) d 30.13. EI-MS: [M]+. Calcd for
5.92 (s, 1H), 5.47 (s, 1H), 3.62 (s, 2H), 1.89* (s, 3H), 1.35 (s, 12H), C22H27BO3 350.21, observed 350.3.
1.27 (s, 12H). 13C NMR (126 MHz, CDCl3) d 139.4*, 138.41,
2-(3-(4-(Allyloxy)phenyl)prop-1-en-2-yl)-4,4,5,5-tetramethyl-1,3,2-
136.2*, 134.5, 133.7*, 131.3, 130.8*, 130.7, 129.5*, 129.4, dioxaborolane (2k) and (Z)-2-(1-(4-(allyloxy)phenyl)prop-1-en-2-yl)-
128.4*, 127.4, 126.6, 126.1*, 83.7, 38.2, 25.00*, 24.9, 16.0*. 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (3k). Synthesized by
11B NMR (128 MHz, CDCl3) d 30.05. EI-MS: [M]+. Calcd for general procedure, isolated as an off yellow oil, 49% yield,
C15H20BClO2 278.12, observed 278.1.
isomeric ratio 2k to 3k is 75 : 25. 1H NMR (500 MHz, CDCl3)
4,4,5,5-Tetramethyl-2-(3-(4-(trifluoromethyl)phenyl)prop-1-en- d 7.35* (d, J = 8.6 Hz, 2H), 7.17* (s, 1H), 7.10 (d, J = 8.4 Hz, 2H),
2-yl)-1,3,2-dioxaborolane (2g) and (Z)-4,4,5,5-Tetramethyl-2-(1-(4- 6.89* (d, J = 8.6 Hz, 2H), 6.82 (d, J = 8.5 Hz, 2H), 6.06 (ddq,
(trifluoromethyl)phenyl)prop-1-en-2-yl)-1,3,2-dioxaborolane (3g). J = 15.7, 10.3, 5.0 Hz, 1H), 5.81–5.79 (m, 1H), 5.51 (s, 1H), 5.41
Synthesized by general procedure, isolated as a yellow oil, 19% (dd, J = 17.2, 10.3 Hz, 1H), 5.28 (t, J = 11.6 Hz, 1H), 4.55* (d, J =
1
yield, 93 : 7 isomeric ratio 2g to 3g. H NMR (500 MHz, CDCl3) 5.2 Hz, 2H), 4.51 (d, J = 5.2 Hz, 2H), 3.41 (s, 2H), 1.99* (s, 3H),
d 7.43 (d, J = 8.0 Hz, 2H), 7.23 (d, J = 7.9 Hz, 2H), 5.80 (d, J = 3.0 Hz, 1.31* (s, 12H), 1.21 (s, 12H). 13C NMR (126 MHz, CDCl3)
1H), 5.48 (d, J = 3.4 Hz, 1H), 3.45 (s, 2H), 1.90* (d, J = 1.9 Hz, 3H), d 157.7*, 156.8, 141.9*, 133.6, 133.3, 133.0, 130.9*, 130.0, 129.4,
1.24* (s, 12H), 1.13 (s, 12H). 13C NMR (126 MHz, CDCl3) d 143.9, 117.7*, 117.4, 114.4, 114.3*, 83.44, 83.4*, 68.9, 68.8*, 40.5, 24.8*,
129.7, 128.3, 127.1 (q, J = 32.2 Hz), 124.5 (q, J = 271.7 Hz), 124.00 24.7, 15.9*. 11B NMR (128 MHz, CDCl3) d 30.02. HRMS: (ESI)
(q, J = 3.8 Hz), 82.6, 40.2, 28.7, 23.6. 11B NMR (128 MHz, CDCl3) [M + H]+ calcd for C18H25BO3 301.20, observed 301.1968.
d 29.80. EI-MS: [M]+. Calcd for C16H20BF3O2 312.15, observed 312.1.
2-(3-Cyclohexylprop-1-en-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxa-
2-(3-(4-Fluorophenyl)prop-1-en-2-yl)-4,4,5,5-tetramethyl-1,3,2-
borolane (2l) and (Z)-2-(1-cyclohexylprop-1-en-2-yl)-4,4,5,5-tetramethyl-
dioxaborolane (2h) and (Z)-2-(1-(4-fluorophenyl)prop-1-en-2-yl)- 1,3,2-dioxaborolane (3l). Synthesized by general procedure, iso-
4,4,5,5-tetramethyl-1,3,2-dioxaborolane (3h). Synthesized by lated as a yellow oil, 84% yield, 78: 22 isomeric ratio 2l to 3l.
general procedure, isolated as a yellow oil, 19% isolated yield, 1H NMR (500 MHz, CDCl3) d 6.11* (d, J = 8.7 Hz, 1H), 5.81–5.70
50% NMR yield, 83: 17 isomeric ratio 2h to 3h. 1H NMR (m, 1H), 5.53 (s, 1H), 2.43–2.26* (m, 1H), 2.03 (d, J = 6.8 Hz, 2H),
New J. Chem.
This journal is © The Royal Society of Chemistry and the Centre National de la Recherche Scientifique 2020